Subscribe To

Price Alert Latest News Economic Calendar News

MRUS / Merus stock jumps 10% after FDA's action on cancer drug

Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a breakthrough therapy designation, intended for expedite the development and review of a drug to treat serious illness. The drug, zenocutuzumab, is geared to the treatment of patients with a type of advanced, metastatic pancreatic cancer. Read More

Demo Live Account See Partner Details

Content Topics

Merus

Stock

Jumps

After

Fda

Action

Cancer

Drug

MRUS

Posted: Jun 29 2023, 16:43

Author Name: Market Watch

MRUS News

By Zacks Investment Research
October 17, 2023

Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help t

By GlobeNewsWire
October 15, 2023

Merus Announces Business Update Conference Call

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinica

By Seeking Alpha
August 30, 2023

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes pro

By Zacks Investment Research
August 7, 2023

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $

By Market Watch
June 29, 2023

Merus stock jumps 10% after FDA's action on cancer drug

Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administr

By Zacks Investment Research
May 11, 2023

Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy

Does Merus N.V. (MRUS) have what it takes to be a top stock pick for momentum investors?

By Zacks Investment Research
May 4, 2023

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $

By Seeking Alpha
April 4, 2023

Merus: Dutch Drug Developer With An Interesting Platform

Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.